12/17/2008

The U.K.'s National Institute for Health and Clinical Excellence endorsed Schering-Plough's Remicade for National Health Service coverage as an alternative for patients with ulcerative colitis who do not respond to ciclosporin.

Full Story:
Reuters

Related Summaries